Evidence map›Paper›PMID 41912912›Full record

ArticleLeukemia2026

The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Maria Agustina Perusini, Katia Pagnano, Carolina Pavlovsky, Daniela Žáčková, Jiří Mayer, Beatriz Moiraghi, Ana Ines Varela, Michele Bianchini, Ana Beatriz Pascoal Lopes, Gislaine Duarte and 9 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Maria Agustina PerusiniDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Katia PagnanoHematology and Hemotherapy Center, University of Campinas, Campinas, Brazil.ORCID http://orcid.org/0000-0001-7975-0805
Carolina PavlovskyFundaleu, Buenos Aires, Argentina.
Daniela ŽáčkováDepartment of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.ORCID http://orcid.org/0000-0001-9802-8148
Jiří MayerDepartment of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.ORCID http://orcid.org/0000-0003-0567-9887
Beatriz MoiraghiHospital General De Agudos J.M. Ramos Mejia, Buenos Aires, Argentina.
Ana Ines VarelaHospital General De Agudos J.M. Ramos Mejia, Buenos Aires, Argentina.ORCID http://orcid.org/0000-0002-4772-3789
Michele BianchiniCIO-FUCA, Instituto Alexander Fleming, Buenos Aires, Argentina, Buenos Aires, Argentina.
Ana Beatriz Pascoal LopesHematology and Hemotherapy Center, University of Campinas, Campinas, AC, Brazil.
Gislaine DuarteHematology and Hemotherapy Center, University of Campinas, Campinas, Brazil.
Carmino Antonio de SouzaHematology and Hemotherapy Center, University of Campinas, Campinas, Brazil.
Ivana JežíškováDepartment of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
Anežka KvetkováDepartment of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
Tomáš JurčekDepartment of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.ORCID http://orcid.org/0000-0002-5283-7406
Hye Won LeeDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Myung Hee ChangDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Jessie J F MedeirosOntario Institute for Cancer Research, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-6597-4613
Sagi AbelsonOntario Institute for Cancer Research, Toronto, ON, Canada.
Dennis Dong Hwan KimDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. dr.dennis.kim@uhn.ca.ORCID http://orcid.org/0000-0003-2640-4911

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41912912

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.